Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance.

The insulinotropic gut hormone glucagon-like peptide (GLP)-1 increases secretory burst mass and the amplitude of pulsatile insulin secretion in healthy volunteers without affecting burst frequency. Effects of GLP-1 on secretory mechanisms in type 2 diabetic patients and subjects with impaired glucose tolerance (IGT) known to have impaired pulsatile release of insulin have not yet been studied. Eight type 2 diabetic patients (64+/-9 years, BMI 28.9+/-7.2 kg/m2, HbA1c 7.7+/-1.3%) and eight subjects with IGT (63+/-10 years, BMI 31.7+/-6.4 kg/m2, HbA1c 5.7+/-0.4) were studied on separate occasions in the fasting state during the continued administration of exogenous GLP-1 (1.2 pmol x kg(-1) x min(-1), started at 10:00 P.M. the evening before) or placebo. For comparison, eight healthy volunteers (62+/-7 years, BMI 27.7+/-4.8 kg/m2, HbA1c 5.4+/-0.5) were studied only with placebo. Blood was sampled continuously over 60 min (roller-pump) in 1-min fractions for the measurement of plasma glucose and insulin. Pulsatile insulin secretion was characterized by deconvolution, autocorrelation, and spectral analysis and by estimating the degree of randomness (approximate entropy). In type 2 diabetic patients, exogenous GLP-1 at approximately 90 pmol/l improved plasma glucose concentrations (6.4+/-2.1 mmol/l vs. placebo 9.8+/-4.1 mmol/l, P = 0.0005) and significantly increased mean insulin burst mass (by 68%, P = 0.007) and amplitude (by 59%, P = 0.006; deconvolution analysis). In IGT subjects, burst mass was increased by 45% (P = 0.019) and amplitude by 38% (P = 0.02). By deconvolution analysis, insulin secretory burst frequency was not affected by GLP-1 in either type 2 diabetic patients (P = 0.15) or IGT subjects (P = 0.76). However, by both autocorrelation and spectral analysis, GLP-1 prolonged the period (lag time) between subsequent maxima of insulin concentrations significantly from approximately 9 to approximately 13 min in both type 2 diabetic patients and IGT subjects. Under placebo conditions, parameters of pulsatile insulin secretion were similar in normal subjects, type 2 diabetic patients, and IGT subjects based on all methodological approaches (P > 0.05). In conclusion, intravenous GLP-1 reduces plasma glucose in type 2 diabetic patients and improves the oscillatory secretion pattern by amplifying insulin secretory burst mass, whereas the oscillatory period determined by autocorrelation and spectral analysis is significantly prolonged. This was not the case for the interpulse interval determined by deconvolution. Together, these results suggest a normalization of the pulsatile pattern of insulin secretion by GLP-1, which supports the future therapeutic use of GLP-1-derived agents.

[1]  J. Holst,et al.  Short-term treatment with GLP-1 increases pulsatile insulin secretion in Type II diabetes with no effect on orderliness , 2000, Diabetologia.

[2]  Steven M. Pincus,et al.  Glucagon-Like Peptide 1 Increases Mass But Not Frequency or Orderliness of Pulsatile Insulin Secretion , 1998, Diabetes.

[3]  J. Holst,et al.  Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[4]  N. Porksen,et al.  In humans at least 75% of insulin secretion arises from punctuated insulin secretory bursts. , 1997, American journal of physiology. Endocrinology and metabolism.

[5]  J. Holst,et al.  Glucagon-like peptide 1 and its potential in the treatment of non-insulin-dependent diabetes mellitus. , 1997, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[6]  J D Veldhuis,et al.  Disorderly and nonstationary insulin secretion in relatives of patients with NIDDM. , 1997, The American journal of physiology.

[7]  N. Porksen,et al.  Mechanisms of Sulfonylurea's Stimulation of Insulin Secretion In Vivo: Selective Amplification of Insulin Secretory Burst Mass , 1996, Diabetes.

[8]  J. Holst,et al.  Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7–36 amide]) in patients with NIDDM , 1996, Diabetologia.

[9]  N. Porksen,et al.  Effects of Glucose Ingestion Versus Infusion on Pulsatile Insulin Secretion: The Incretin Effect Is Achieved by Amplification of Insulin Secretory Burst Mass , 1996, Diabetes.

[10]  N. Porksen,et al.  Effects of somatostatin on pulsatile insulin secretion: elective inhibition of insulin burst mass. , 1996, The American journal of physiology.

[11]  L. Wildt,et al.  A simple device for serial blood collection in human subjects and animals. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[12]  N. Porksen,et al.  Impact of sampling technique on appraisal of pulsatile insulin secretion by deconvolution and cluster analysis. , 1995, The American journal of physiology.

[13]  N. Porksen,et al.  Pulsatile insulin secretion accounts for 70% of total insulin secretion during fasting. , 1995, The American journal of physiology.

[14]  J. Holst,et al.  Proglucagon processing in porcine and human pancreas. , 1994, The Journal of biological chemistry.

[15]  K. Alberti,et al.  Augmented effect of short-term pulsatile versus continuous insulin delivery on lipid metabolism but similar effect on whole-body glucose metabolism in obese subjects. , 1994, Metabolism: clinical and experimental.

[16]  M. Nauck,et al.  Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. , 1993, The Journal of clinical endocrinology and metabolism.

[17]  J. Habener,et al.  Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37) , 1993, Nature.

[18]  B. Göke,et al.  Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide-1 (7–36) amide on the rat pancreas , 1993 .

[19]  J. Holst,et al.  Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. , 1993, The Journal of clinical investigation.

[20]  J. Holst,et al.  Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. , 1992, The New England journal of medicine.

[21]  S M Pincus,et al.  Approximate entropy as a measure of system complexity. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[22]  P. A. Blight.  The Analysis of Time Series: An Introduction , 1991 .

[23]  G. Paolisso,et al.  Pulsatile insulin delivery has greater metabolic effects than continuous hormone administration in man: importance of pulse frequency. , 1991, The Journal of clinical endocrinology and metabolism.

[24]  R. Robertson.  Type II Diabetes, Glucose “Non-Sense,” and Islet Desensitization , 1989, Diabetes.

[25]  K. Polonsky,et al.  Glyburide enhances the responsiveness of the beta-cell to glucose but does not correct the abnormal patterns of insulin secretion in noninsulin-dependent diabetes mellitus. , 1989, The Journal of clinical endocrinology and metabolism.

[26]  S. O’Rahilly,et al.  Impaired pulsatile secretion of insulin in relatives of patients with non-insulin-dependent diabetes. , 1988, The New England journal of medicine.

[27]  S. Bloom,et al.  GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN , 1987, The Lancet.

[28]  M L Johnson,et al.  The pituitary gland secretes in bursts: appraising the nature of glandular secretory impulses by simultaneous multiple-parameter deconvolution of plasma hormone concentrations. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Holst,et al.  Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2). , 1987, Scandinavian journal of clinical and laboratory investigation.

[30]  J. Halter,et al.  Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. , 1984, The Journal of clinical investigation.

[31]  R. Turner,et al.  Pulsatile Insulin Has Greater Hypoglycemic Effect Than Continuous Delivery , 1983, Diabetes.

[32]  R. Wolfe,et al.  Rapid oscillations in plasma insulin, glucagon, and glucose in obese and normal weight humans. , 1982, The Journal of clinical endocrinology and metabolism.

[33]  R. Turner,et al.  Brief, Irregular Oscillations of Basal Plasma Insulin and Glucose Concentrations in Diabetic Man , 1981, Diabetes.

[34]  G. Weir,et al.  Sustained oscillations of insulin, glucagon, and somatostatin from the isolated canine pancreas during exposure to a constant glucose concentration. , 1980, The Journal of clinical investigation.

[35]  R. Turner,et al.  Cyclic oscillations of basal plasma glucose and insulin concentrations in human beings. , 1979, The New England journal of medicine.

[36]  C. J. Goodner,et al.  Insulin, glucagon, and glucose exhibit synchronous, sustained oscillations in fasting monkeys. , 1977, Science.